21 December 2023
Posted by Macquarie Asset Management
This article has been written by Walter Scott & Partners Limited (‘Walter Scott’). The Walter Scott Global Equity Fund is proudly brought to you by Macquarie Professional Series.
If you only have one minute …
- Walter Scott’s Investment Managers, Lindsay Scott and Jamie Zegleman travelled to Italy in late September 2023 to meet with select companies across healthcare, industrial, technology and luxury sectors.
- Business in Italy is often thought of as inefficient, inward thinking and in industrial decline, however the nation is in fact home to some world-leading companies with strong competitive positions in particular industry niches, and compelling international vision and appetite for growth.
- The trip was a valuable reminder of a different view, one of corporate success and innovation.
Italy’s proud industrial legacy in 2023
Like many of its European peers, Italy has a long and proud industrial history. That legacy might be most commonly associated with its many automobile marques, but its industrial expertise is also very evident in pharmaceuticals and healthcare and during our travels we met a number of companies with proven track records in delivering technology and processes to support automation, improve efficiency and meet the evolving needs of longstanding customers.
Founded in 1949, Stevanato Group devises systems and processes for its healthcare partners allowing drug delivery that is both safe and easy-to-use. During the trip we were able to visit one of the company’s sites viewing a syringe production facility as well as R&D and engineering centres. For us, there was a valuable read across into the GLP-1 space that has become so high profile, with importance not only to the future growth of Novo Nordisk and Eli Lilly amongst others, but with potentially profound implications for healthcare and highly processed foods and beverages. Through its expertise in precision engineering and track record in innovation across automation and control, Stevanato’s current workaround drug containment solutions, drug delivery systems including auto injection and wearables is also aligned with areas of growth within this sector, growth underpinned by fundamental demographic and technological trends.
It was a similar story of cutting-edge innovation during our meeting with DiaSorin, a specialist operator in the in-vitro diagnostics (IVD) industry with particular strength in the immunodiagnostics market.
"Offer(ing) services above and beyond those available from the big players”
We also met with Amplifon, the global leading hearing aid and hearing service provider and Essilor Luxottica, which holds a similar global-leading position in eyecare. The outlook for both companies is not only underpinned by rising living standards and demographic trends but also innovation that deepens their competitive position and enhances the day-to-day lives of their customers.
Another meeting in this sector was with specialised pharmaceutical and rare disease business Recordati.
"Its focus on niches within immunology, oncology and metabolic diseases has proved very successful”
With its branded generics providing a cash generating backbone to the company, we talked more about its rare disease business which has grown to a third of its sales. Here the company was early to identify the opportunity in this market and its focus on niches within immunology, oncology and metabolic diseases has proved very successful. With acquisitions very much part of the company’s future plans, we also discussed the company’s more recent purchase of two urology products from GSK, to better understand how those assets are incorporated into the business and the strategy that is then put in place to increase the rate of growth.
A fashion capital
Luxury is another area that is as synonymous with Milan as it is with Paris and meetings with both Prada and Moncler provided valuable insight into the current marketplace. At Moncler, we met with the Group’s Chief Corporate & Supply Officer as well as the Chief Brand Officer, a 25-year veteran of Nike amongst other finance and brand roles. They outlined plans for the careful extension of the Moncler offer across all seasons and an accompanying store roll out plan. Both companies spoke about the current renaissance in ‘quiet luxury’ that we have heard from others in this sector, and a trend that we’ve seen negatively impact Kering’s Gucci in particular. China was also, of course, a key topic of conversation with both Moncler and Prada noting that travel by the Chinese consumer and spending in Europe is still limited. Moncler attributed this to lack of flights to Europe, but both were confident that travel, and spending, at pre-Covid19 levels would resume at some point.
We also learnt more about what might be perceived as luxury gym equipment in a meeting with Technogym. Understandably keen to set themselves apart from Peloton, management were also quick to dispel any myth that they are merely a successful provider of equipment to high-end gyms and hotels.
"From electronics in the 1990s to AI today”
We learnt more about the company’s widening customer base as well as the increasingly important service element. We heard about the evolution from a focus on electronics in the 1990s to AI today, with data now central to the services that go along with the equipment. In management’s view this moves the company into a healthcare market, rather than a narrow exercise market, with services to address the impact of aging and to support longer and healthier lives. There are also services to support rehabilitation with the company currently working with12,000 rehabilitation centres.
Family and founders
Another defining characteristic of Italy’s corporate landscape, and many of its success stories, has been the prevalence of family-owned and founder-led companies. In our conversations with both Recordati, and Technogym we were left in no doubt about the positive arguments for ongoing founder and family ownership and involvement in listed companies.
In addition to the benefits of having a strategic long-term shareholder with an enduring (and often multi-generational) commitment to the company, it also enables such companies to invest with a long-term focus. These types of companies are often able to take strategic chances and to pursue growth opportunities that companies entirely beholden to meeting quarterly earnings targets might have to forgo. There is a balance to be struck of course. When considering investments in such businesses, we do also seek commensurate corporate governance practices to minimise risks to minority shareholders. Significant representation from independent directors on the board, for example, helps to ensure that the benefits from long-term founder and family involvement are maximised.
Long-term thinking
That same long-term message came through in a meeting with Intercos, company that acts as a CDMO (contract development and manufacturing organisation) for the cosmetics industry and where the founder Dario Ferrari retains 32% of the business. Whilst we might more often think of the important, and growing role of CDMOs, like Lonza or Sartoriusin pharmaceutical manufacturing, Intercos has an equivalently important place in the supply chain of make-up skincare and hair & body brands. It is one of the few global players supplying all the big brands including L’Oréal. In that context this meeting also provided an interesting look behind the R&D and innovation curtain of the cosmetics industry.
"An interesting look behind the R&D and innovation curtain of the cosmetics industry”
Reporting back
Research trips form an important part of our overall research process which spans desk-based research, engagement with companies and conversations with industry experts. Dialogue, both exchange of ideas and challenge, within the Research team is another critical part of that process as is reporting back from research trips, sharing both information and impressions.
In reporting back from Italy, the message was one of distinct optimism.
The itineraries for all our research trips are of course planned around meetings with companies that have already met our investment criteria, or have the potential to, and so the content and tone of our conversations with the companies that we met within Italy cannot be viewed as a proxy for the country’s general corporate mood. However, contrary to the often-downbeat common consensus on Italy, every company we met with outlined an innovative and ambitious strategy for international growth.
At our Research Conference in Edinburgh back in May 2023, former Prime Minister of Italy, Matteo Renzi regretfully observed that so often he is told that Italy might be considered very good museum, indeed probably one of the best museums in the world; very beautiful but without possibilities for business. In a follow up call with the Research team during the summer, he made the same observation but then made the case for Italy with examples of supportive government policy to attract skilled individuals as well as finance into the country’s corporate sector. Whilst we wouldn’t say that Italy has redressed its PR problem, and those government policies certainly have some way to go, the companies we met with were far from museum relics.
"Contrary to the often-downbeat common consensus on Italy, every company we met with outlined an innovative and ambitious strategy”
Important information
The Walter Scott Global Equity Fund is designed for investors who are seeking capital growth, are intending to use the Fund as a satellite within a portfolio, have a medium to long-term investment timeframe, have a high or very high risk/return profile and require the ability to have daily access to capital. Please review the Target Market Determination for the relevant Fund available at macquarie.com/mam/tmd and consider if the Fund may be suitable for you.
This information has been prepared by Macquarie Investment Management Australia Limited (ABN 55 092 552 611 AFSL No. 238321), the issuer and responsible entity of the Funds referred to above. This is general information only and does not take account of investment objectives, financial situation or needs of any person. It should not be relied upon in determining whether to invest in a Fund. In deciding whether to acquire or continue to hold an investment in a Fund, an investor should consider the relevant Fund’s product disclosure statement. The product disclosure statement is available on our website at macquarie.com/mam/pds or by contacting us on 1800 814 523. This information is intended for recipients in Australia only.
Macquarie has appointed Walter Scott & Partners Limited (Walter Scott) as investment manager of the Walter Scott Global Equity Fund and the Walter Scott Emerging Markets Fund. Walter Scott is an investment management firm authorised and regulated in the United Kingdom by the Financial Conduct Authority in the conduct of investment business. Walter Scott is a wholly-owned subsidiary of The Bank of New York Mellon Corporation.
Nothing in this document constitutes a recommendation to buy, sell or hold any security or instrument.
Future results are impossible to predict. This document contains opinions, conclusions, estimates and other forward-looking statements which are, by their very nature, subject to various risks and uncertainties. Actual events or results may differ materially, positively or negatively, from those reflected or contemplated in such forward-looking statements.
Past performance information shown herein, is not a reliable indicator of future performance.
No representation or warranty, express or implied, is made as to the suitability, accuracy, currency or completeness of the information, opinions and conclusions contained in this document. In preparing the document, reliance has been placed, without independent verification, on the accuracy and completeness of information available from external sources. To the maximum extent permitted by law, no member of the Macquarie Group nor its directors, employees or agents accept any liability for any loss arising from the use of this document, its contents or otherwise arising in connection with it.
Other than Macquarie Bank Limited ABN 46 008 583 542 (“Macquarie Bank”), any Macquarie Group entity noted in this material is not an authorised deposit-taking institution for the purposes of the Banking Act 1959 (Commonwealth of Australia). The obligations of these other Macquarie Group entities do not represent deposits or other liabilities of Macquarie Bank. Macquarie Bank does not guarantee or otherwise provide assurance in respect of the obligations of these other Macquarie Group entities. In addition, if this document relates to an investment, (a) the investor is subject to investment risk including possible delays in repayment and loss of income and principal invested and (b) none of Macquarie Bank or any other Macquarie Group entity guarantees any particular rate of return on or the performance of the investment, nor do they guarantee repayment of capital in respect of the investment.
© 2023 Macquarie Group Limited